Steps and routes of HCV infection: The great promise of new anti-viral targets

Current Drug Targets

Volumn 16, Issue 7, 2015, Pages 757-770

  Crema, Annalisa ^a   Ponzetto, Antonio ^b   Clementi, Massimo ^c   Carloni, Guido ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

HCV infection; Immune pathogenesis; Life cycle and targets; Spread and propagation; Steps and pathways

Indexed keywords

BOCEPREVIR; CD81 ANTIGEN; CELL RECEPTOR; CLAUDIN; CYCLOPHILIN A; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HELICASE; HEPATITIS C VACCINE; LEDIPASVIR; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NEUTRALIZING ANTIBODY; OCCLUDIN; PEGINTERFERON ALPHA2B; RITONAVIR; RNA DIRECTED RNA POLYMERASE; SCAVENGER RECEPTOR BI; SIMEPREVIR; SMALL INTERFERING RNA; SOFOSBUVIR; TELAPREVIR; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; ANTIVIRUS AGENT; HEPATITIS VACCINE;

ANTIGEN BINDING; ARTICLE; CELL CONTACT; CELL MEMBRANE; ENDOCYTOSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HUMAN; IMMUNE RESPONSE; LIFE CYCLE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RNA TRANSLATION; VIRION; VIRUS ENTRY; VIRUS MORPHOGENESIS; VIRUS REPLICATION; ANIMAL; DRUG EFFECTS; HEPACIVIRUS; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL HEPATITIS VACCINES; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84939808493     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150213111603     Document Type: Article

References (177)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142(6): 1264-73 e1.
2. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol2005; 43(4): 550-2.
3. Lavanchy D. Viral Hepatitis: global goals for vaccination. J Clin Virol 2012; 55(4): 269-302.
4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244(4902): 359-62.
5. Gastaminza P, Dryden KA, Boyd B, et al. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010; 84(21): 10999-1009.
6. Catanese MT, Uryu K, Kopp M, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA 2013; 110(23): 9505-10.
7. Bartenschlager R, Kaul A, Sparacio S. Replication of the hepatitis C virus in cell culture. Antiviral Res 2003; 60(2): 91-102.
8. Steinmann E, Pietschmann T. Cell culture systems for hepatitis C virus. Curr Top Microbiol Immunol 2013; 369: 17-48.
9. Kuo G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science1989; 244(4902): 362-4.
10. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30(4): 333-47.
11. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol 2013; 11(10): 688-700.
12. Lohmann V. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol 2013; 369: 167-98.
13. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5(6): 453-63.
14. Gottwein JM, Bukh J. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res 2008; 71: 51-133.
15. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 2006; 44(3): 527-35.
16. Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011; 3(11): 2280-300.
17. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol 2014; 61(1S): S14-S25.
18. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88(8): 3392-6.
19. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66(5): 3225-9.
20. Simmonds P. Genetic diversity and evolution of hepatitis C virus-- 15 years on. J Gen Virol 2004; 85(Pt 11): 3173-88.
21. Morel V, Fournier C, Francois C, et al. Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat 2011; 18(2): 77-83.
22. Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol 2009; 6(4): 217-27.
23. Weiner AJ, Brauer MJ, Rosenblatt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180(2): 842-8.
24. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288(5464): 339-44.
25. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001; 75(12): 5703-10.
26. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132(2): 667- 78.
27. Lavillette D, Tarr AW, Voisset C, et al. Characterization of hostrange and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 2005; 41(2): 265-74.
28. von Hahn T, McKeating JA. In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube. J Hepatol 2007; 46(3): 355-8.
29. Vercauteren K, Mesalam AA, Leroux-Roels G, Meuleman P. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization. World J Gastroenterol 2014; 20(43): 15975-91.
30. Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. Semin Immunopathol 2013; 35(1): 87-100.
31. de Almeida AJ, Campos-de-Magalhaes M, de Melo Marcal OP, et al. Hepatitis C virus-associated thrombocytopenia: a controlled prospective, virological study. Ann Hematol 2004; 83(7): 434-40.
32. Diaz O, Delers F, Maynard M, et al. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006; 87(Pt 10): 2983-91.
33. Zahn A, Jennings N, Ouwehand WH, Allain JP. Hepatitis C virus interacts with human platelet glycoprotein VI. J Gen Virol 2006; 87(Pt 8): 2243-51.
34. Crotta S, Stilla A, Wack A, et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002; 195(1): 35-41.
35. Tseng CT, Klimpel GR. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 2002; 195(1): 43-9.
36. Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leukoc Biol 2004; 76(4): 743-59.
37. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5(10): 996- 1002.
38. De Maria A, Fogli M, Mazza S, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007; 37(2): 445-55.
39. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137(3): 1151-60, 60 e1-7.
40. Sene D, Levasseur F, Abel M, et al. Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5Amediated imbalance of inflammatory cytokines. PLoS Pathog 2010; 6(11): e1001184.
41. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25(2): 449- 58.
42. Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302(5645): 659-62.
43. Neumann-Haefelin C, Thimme R. Success and failure of virusspecific T cell responses in hepatitis C virus infection. Dig Dis 2011; 29(4): 416-22.
44. Wahid A, Dubuisson J. Virus-neutralizing antibodies to hepatitis C virus. J Viral Hepat 2013; 20(6): 369-76.
45. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2(9): 706-13.
46. Bartosch B, Bukh J, Meunier JC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci USA 2003; 100(24): 14199-204.
47. Yu MY, Bartosch B, Zhang P, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti- HCV-positive plasma. Proc Natl Acad Sci USA 2004; 101(20): 7705-10.
48. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virusneutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104(14): 6025- 30.
49. Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 2008; 48(1): 299-307.
50. Stamataki Z, Grove J, Balfe P, McKeating JA. Hepatitis C virus entry and neutralization. Clin Liver Dis 2008; 12(3): 693-712, x.
51. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11(7): 791-6.
52. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102(26): 9294-9.
53. Haberstroh A, Schnober EK, Zeisel MB, et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008; 135(5): 1719-28 e1.
54. Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14(1): 25-7.
55. Burioni R, Perotti M, Mancini N, Clementi M. Perspectives for the utilization of neutralizing human monoclonal antibodies as anti- HCV drugs. J Hepatol 2008; 49(2): 299-300.
56. Houghton M, Law JL, Tyrrell DL. An inactivated hepatitis C virus vaccine on the horizon? Gastroenterology 2013; 145(2): 285-8.
57. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: A distant peak still worth climbing. J Hepatol 2014; 61(1S): S34-S44.
58. Honegger JR, Zhou Y, Walker CM. Will there be a vaccine to prevent HCV infection? Semin Liver Dis 2014; 34(1): 79-88.
59. Wong JA, Bhat R, Hockman D, et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol 2014; 88(24): 14278-88.
60. Al Olaby RR, Cocquerel L, Zemla A, et al. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein. PLoS One 2014; 9(10): e111333.
61. Chmielewska AM, Naddeo M, Capone S, et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol 2014; 88(10): 5502-10.
62. Xue J, Zhu H, Chen Z. Therapeutic vaccines against hepatitis C virus. Infect Genet Evol 2014; 22: 120-9.
63. Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 2014; 6(261): 261ra153.
64. Lohmann V, Bartenschlager R. On the history of hepatitis C virus cell culture systems. J Med Chem 2014; 57(5): 1627-42.
65. Masaki T, Matsunaga S, Takahashi H, et al. Involvement of hepatitis C virus NS5A hyperphosphorylation mediated by casein kinase I-alpha in infectious virus production. J Virol 2014; 88(13): 7541- 55.
66. Huang Y, Staschke K, De Francesco R, Tan SL. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 2007; 364(1): 1-9.
67. Reghellin V, Donnici L, Fenu S, et al. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIalpha complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes. Antimicrob Agents Chemother 2014; 58(12): 7128-40.
68. Ross-Thriepland D, Mankouri J, Harris M. Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes. J Virol 2005; 89(6): 3123-35.
69. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436(7053): 933-8.
70. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103(19): 7408-13.
71. Suzuki R, Saito K, Kato T, et al. Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection. Virology 2012; 432(1): 29-38.
72. Vieyres G, Pietschmann T. Entry and replication of recombinant hepatitis C viruses in cell culture. Methods 2012; 59(2): 233-48.
73. Shulla A, Randall G. Hepatitis C virus-host interactions, replication, and viral assembly. Curr Opin Virol 2012; 2(6): 725-32.
74. Wu X, Robotham JM, Lee E, et al. Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 2012; 8(4): e1002617.
75. Roelandt P, Obeid S, Paeshuyse J, et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012; 57(2): 246-51.
76. Schwartz RE, Trehan K, Andrus L, et al. Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109(7): 2544-8.
77. von Hahn T, Rice CM. Hepatitis C virus entry. J Biol Chem 2008; 283(7): 3689-93.
78. Blanchard E, Belouzard S, Goueslain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 2006; 80(14): 6964-72.
79. Codran A, Royer C, Jaeck D, et al. Entry of hepatitis C virus pseudotypes into primary human hepatocytes by clathrin-dependent endocytosis. J Gen Virol 2006; 87(Pt 9): 2583-93.
80. Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opin Virol 2012; 2(1): 14-9.
81. Meertens L, Bertaux C, Cukierman L, et al. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus. J Virol 2008; 82(7): 3555-60.
82. Yang W, Qiu C, Biswas N, et al. Correlation of the tight junctionlike distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J Biol Chem 2008; 283(13): 8643-53.
83. Brazzoli M, Bianchi A, Filippini S, et al. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol 2008; 82(17): 8316-29.
84. Coller KE, Berger KL, Heaton NS, Cooper JD, Yoon R, Randall G. RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog 2009; 5(12): e1000702.
85. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100(12): 7271-6.
86. Kobayashi M, Bennett MC, Bercot T, Singh IR. Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay. J Virol 2006; 80(4): 1817-25.
87. Sieczkarski SB, Whittaker GR. Dissecting virus entry via endocytosis. J Gen Virol 2002; 83(Pt 7): 1535-45.
88. Lavillette D, Pecheur EI, Donot P, et al. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol 2007; 81(16): 8752-65.
89. Lavillette D, Bartosch B, Nourrisson D, et al. Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem 2006; 281(7): 3909-17.
90. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 2006; 80(4): 1734- 41.
91. Dreux M, Boson B, Ricard-Blum S, et al. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 2007; 282(44): 32357-69.
92. Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology 2006; 348(1): 1-12.
93. Sharma NR, Mateu G, Dreux M, Grakoui A, Cosset FL, Melikyan GB. Hepatitis C virus is primed by CD81 protein for low pHdependent fusion. J Biol Chem 2011; 286(35): 30361-76.
94. Anggakusuma, Colpitts CC, Schang LM, et al. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 2014; 63(7): 1137-49.
95. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17(5): 589-95.
96. Sainz B, Jr., Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012; 18(2): 281-5.
97. Barretto N, Sainz B, Jr., Hussain S, Uprichard SL. Determining the involvement and therapeutic implications of host cellular factors in hepatitis c virus cell-to-cell spread. J Virol 2014; 88(9): 5050-61.
98. Roohvand F, Maillard P, Lavergne JP, et al. Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. J Biol Chem 2009; 284(20): 13778- 91.
99. Lai CK, Jeng KS, Machida K, Lai MM. Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A. J Virol 2008; 82(17): 8838-48.
100. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009; 90(Pt 5): 1055-70.
101. Dubuisson J, Popescu CI. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell 2010; 102(1): 63-74.
102. Gouttenoire J, Penin F, Moradpour D. Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 2010; 20(2): 117-29.
103. Moriishi K, Matsuura Y. Host factors involved in the replication of hepatitis C virus. Rev Med Virol 2007; 17(5): 343-54.
104. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 2013; 11(7): 482-96.
105. Murray CL, Jones CT, Rice CM. Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol 2008; 6(9): 699-708.
106. Khromykh AA, Meka H, Guyatt KJ, Westaway EG. Essential role of cyclization sequences in flavivirus RNA replication. J Virol 2001; 75(14): 6719-28.
107. You S, Stump DD, Branch AD, Rice CM. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 2004; 78(3): 1352-66.
108. Pedersen IM, Cheng G, Wieland S, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449(7164): 919-22.
109. Randall G, Panis M, Cooper JD, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007; 104(31): 12884-9.
110. Hobert O. Gene regulation by transcription factors and microRNAs. Science 2008; 319(5871): 1785-6.
111. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309(5740): 1577-81.
112. Lanford RE, Bigger C. Advances in model systems for hepatitis C virus research. Virology 2002; 293(1): 1-9.
113. Romero-Lopez C, Berzal-Herranz A. A long-range RNA-RNA interaction between the 5' and 3' ends of the HCV genome. RNA 2009; 15(9): 1740-52.
114. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53(5): 1742-51.
115. Afdhal NH, Zeuzem S, Schooley RT, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepatol 2013; 20(11): 745-60.
116. Vogt DA, Camus G, Herker E, et al. Lipid droplet-binding protein TIP47 regulates hepatitis C Virus RNA replication through interaction with the viral NS5A protein. PLoS Pathog 2013; 9(4): e1003302.
117. Pietschmann T, Zayas M, Meuleman P, et al. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog 2009; 5(6): e1000475.
118. Rosina F, Tosti ME, Borghesio E, et al. Pegylated interferon alpha plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. Dig Liver Dis 2014; 46(9): 826-32.
119. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with longterm peginterferon. Hepatology 2011; 53(4): 1100-8.
120. Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. J Hepatol 2005; 43(4): 590- 8.
121. Labarga P, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. Antivir Ther 2015; 20(3): 329-34.
122. Chae HB, Park SM, Youn SJ. Direct-acting antivirals for the treatment of chronic hepatitis C: open issues and future perspectives. SciWorldJ 2013; 2013: 704912.
123. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepatol 2012; 19(8): 525-36.
124. Koretz RL. Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1. Ann Intern Med 2014; 161(10): JC11.
125. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368(1): 34-44.
126. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 2014; 7(3): 131-40.
127. Cholongitas E, Papatheodoridis GV. Sofosbuvir: a novel oral agent for chronic hepatitis C. Ann Gastroenterol 2014; 27(4): 331-7.
128. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370(21): 1993-2001.
129. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370(16): 1483-93.
130. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370(20): 1889-98.
131. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370(20): 1879-88.
132. Osinusi A, Bon D, Nelson A, et al. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. J Med Virol 2014; 86(2): 177-85.
133. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384(9956): 1756-65.
134. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370(21): 1983-92.
135. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370(21): 1973-82.
136. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370(17): 1594-603.
137. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19(2): 95-103.
138. Benga WJ, Krieger SE, Dimitrova M, et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010; 51(1): 43-53.
139. Tews BA, Popescu CI, Dubuisson J. Last stop before exit - hepatitis C assembly and release as antiviral drug targets. Viruses 2010; 2(8): 1782-803.
140. Meredith LW, Zitzmann N, McKeating JA. Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Antiviral Res 2013; 100(3): 636-9.
141. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013; 369: 289-320.
142. Liu Z, He JJ. Cell-cell contact-mediated hepatitis C virus (HCV) transfer, productive infection, and replication and their requirement for HCV receptors. J Virol 2013; 87(15): 8545-58.
143. Zhong P, Agosto LM, Munro JB, Mothes W. Cell-to-cell transmission of viruses. Curr Opin Virol 2013; 3(1): 44-50.
144. Sattentau Q. Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol 2008; 6(11): 815-26.
145. Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. J Gen Virol 2000; 81(Pt 6): 1413-29.
146. Benovic S, Kok T, Stephenson A, McInnes J, Burrell C, Li P. De novo reverse transcription of HTLV-1 following cell-to-cell transmission of infection. Virology1998; 244(2): 294-301.
147. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-tocell transmission of human immunodeficiency virus infection from monocyte-derived macrophages to peripheral blood lymphocytes. Virology 1999; 265(2): 319-29.
148. Gupta P, Balachandran R, Ho M, Enrico A, Rinaldo C. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol 1989; 63(5): 2361-5.
149. Igakura T, Stinchcombe JC, Goon PK, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299(5613): 1713-6.
150. Maldarelli F, Sato H, Berthold E, Orenstein J, Martin MA. Rapid induction of apoptosis by cell-to-cell transmission of human immunodeficiency virus type 1. J Virol 1995; 69(10): 6457-65.
151. Muratori C, Sistigu A, Ruggiero E, et al. Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9. J Virol 2007; 81(17): 9078-87.
152. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 2000; 1(1): 23-9.
153. Davis DM, Igakura T, McCann FE, et al. The protean immune cell synapse: a supramolecular structure with many functions. Semin Immunol 2003; 15(6): 317-24.
154. Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J Clin Invest 2004; 114(5): 605-10.
155. Dustin M. Viral spread through protoplasmic kiss. Nat Cell Biol 2003; 5(4): 271-2.
156. Onfelt B, Nedvetzki S, Yanagi K, Davis DM. Cutting edge: Membrane nanotubes connect immune cells. J Immunol 2004; 173(3): 1511-3.
157. Sowinski S, Jolly C, Berninghausen O, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol 2008; 10(2): 211-9.
158. Timpe JM, Stamataki Z, Jennings A, et al. Hepatitis C virus cellcell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008; 47(1): 17-24.
159. Valli MB, Serafino A, Crema A, et al. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol 2006; 78(2): 192- 201.
160. Valli MB, Crema A, Lanzilli G, et al. Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro. J Med Virol 2007; 79(10): 1491-9.
161. Witteveldt J, Evans MJ, Bitzegeio J, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009; 90(Pt 1): 48-58.
162. Tarr AW, Lafaye P, Meredith L, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; 58(3): 932-9.
163. Russell RS, Meunier JC, Takikawa S, et al. Advantages of a singlecycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci USA 2008; 105(11): 4370-5.
164. Fofana I, Xiao F, Thumann C, et al. A novel monoclonal anti- CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission. PLoS One 2013; 8(5): e64221.
165. Brimacombe CL, Grove J, Meredith LW, et al. Neutralizing antibody- resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85(1): 596-605.
166. Syder AJ, Lee H, Zeisel MB, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54(1): 48-55.
167. Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol 2013; 87(15): 8282-93.
168. Mee CJ, Harris HJ, Farquhar MJ, et al. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol 2009; 83(12): 6211-21.
169. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103(15): 6001-6.
170. Johnson DC, Huber MT. Directed egress of animal viruses promotes cell-to-cell spread. J Virol 2002; 76(1): 1-8.
171. Mothes W, Sherer NM, Jin J, Zhong P. Virus cell-to-cell transmission. J Virol 2010; 84(17): 8360-8.
172. Dreux M, Garaigorta U, Boyd B, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 2012; 12(4): 558-70.
173. Ramakrishnaiah V, Thumann C, Fofana I, et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proc Natl Acad Sci USA 2013; 110(32): 13109-13.
174. Zeisel MB, Felmlee DJ, Baumert TF. Hepatitis C virus entry. Curr Top Microbiol Immunol 2013; 369: 87-112.
175. Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012; 93(Pt 1): 1-19.
176. Xiao F, Fofana I, Heydmann L, et al. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents. PLoS Pathog 2014; 10(5): e1004128.
177. Callendret B, Eccleston HB, Hall S, et al. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology 2014; 60(5): 1531-40.